Kalani, Komal; Chaturvedi, Vinita; Trivedi, Priyanka; Tondon, Sudeep; Srivastava, Santosh Kumar published the artcile< Dihydroartemisinin and its Analogs: A New Class of Antitubercular Agents>, Application of C9H7ClO, the main research area is Mycobacterium dihydroartemisinin antitubercular agent; Anti-tubercular activity; Dihydroartemisinin; Semi-synthetic derivatives; Synergistic effect Artemisia annua; Tuberculosis..
Chem. transformation of dihydroartemisinin for anti-tubercular lead optimization. Dihydroartemisinin, a metabolite of artemisinin was chem. converted into eight acyl derivatives and were evaluated for anti-tubercular potential against H37Rv virulent strain of Mycobacterium tuberculosis by agar-based proportion assay. Further, synergistic activity of 12-O-m-anisoyl dihydroartemisinin was also studied with the front-line anti-TB drugs, isoniazid and rifampicin. Results: The results showed that all the derivatives were active but out of eight, 12-O-m-anisoyl dihydroartemisinin and 12-O-p-anisoyl dihydroartemisinin were significantly active (MIC 25.0μg/mL). In synergistic activity evaluation, the 12-O-m-anisoyl dihydroartemisinin derivative showed reduction in MIC (by 1/8th, i.e. 3.12μg/mL and that of rifampicin by 1/4th, i.e. 0.05μg/mL) with the front-line anti-TB drug, rifampicin. The sumfractional inhibitory concentration (Σ FIC) was 0.375. These results suggested a synergistic effect of the 12-O-m-anisoyl dihydroartemisinin with rifampicin and established its base for the development of anti-tubercular agents from an in-expensive and non-toxic natural product. To the best of our knowledge this is the first ever report on the anti-tubercular potential of dihydroartemisinin and its derivatives
Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates) published new progress about Mycobacterium tuberculosis. 17082-09-6 belongs to class chlorides-buliding-blocks, and the molecular formula is C9H7ClO, Application of C9H7ClO.
Referemce:
Chloride – Wikipedia,
Chlorides – an overview | ScienceDirect Topics